Boyer P J, Fahey J L
Cancer Res. 1976 Apr;36(4):1492-8.
Two characteristics of immune responses to weakly immunogenic plasma cell tumors were demonstrated in this study. (a) Elevated lymphoproliferative responses following in vivo inoculation of sublethal doses of plasma cell tumors were detected by a mixed lymphocyte-tumor interaction (MLTI) assay. Specificity of elevated MLTI responses correlated with resistance to in vivo tumor challenge. These responses were dependent upon the presence of thymus-derived cells. (b) Spleen and lymph node cells showed markedly different patterns of MLTI activity following plasma cell tumor immunization. Spleen cell responses were depressed for the first 30 days postimmunization, whereas lymph node cells showed augmented MLTI reactivity immediately after immunization. These observations indicated that lymphocyte populations from different lymphoid organs may show widely dissimilar responses in vitro at the same point in the in vivo development of tumor resistance.
本研究证实了对弱免疫原性浆细胞瘤免疫反应的两个特征。(a) 通过混合淋巴细胞-肿瘤相互作用(MLTI)试验检测到,在体内接种亚致死剂量的浆细胞瘤后,淋巴细胞增殖反应增强。MLTI反应增强的特异性与体内肿瘤攻击的抗性相关。这些反应依赖于胸腺来源细胞的存在。(b) 浆细胞瘤免疫后,脾脏和淋巴结细胞显示出明显不同的MLTI活性模式。免疫后第1个30天脾脏细胞反应受到抑制,而淋巴结细胞在免疫后立即显示出增强的MLTI反应性。这些观察结果表明,在肿瘤抗性体内发育的同一时间点,来自不同淋巴器官的淋巴细胞群体在体外可能表现出广泛不同的反应。